>FGL1 A Novel Immune Inhibitor of LAG-3
FGL1 is a member of the fibrinogen protein family, which is expressed at low levels in the liver under normal circumstances. But it is highly expressed in many types of cancers such as prostate cancer and melanoma. The latest research shows that FGL1 is a hot immune inhibitory ligand of LAG-3. Blocking FGL1 / LAG-3 interaction can improve the body's immunity and slow down tumor growth.
ACROBiosystems has developed FGL1 protein expressed by HEK293 with a variety of species (Human, Mouse, Cyno) and tags (Fc, His), and AviTagTM biotinylated FGL1 protein can help your drug development. ACRO has verified the purity and activity of FGL1 protein and protocols are offered.
|Molecule||Cat. No.||Host||Product Description|
|FG1-H52Hy||Human||FGL1 Protein, His Tag|
|FG1-H5258||Human||FGL1 Protein, Fc Tag|
|FG1-H82F4||Human||Biotinylated FGL1 Protein, Avitag™,Fc Tag|
|FG1-C5269||Cynomolgus / Rhesus macaque||FGL1 Protein, Fc Tag|
|FG1-H82Ey||Human||Biotinylated FGL1 Protein, His, Avitag™|
FGL1 has been identified as a hot immune inhibitory ligand of LAG-3 products. If you are interested in LAG-3, please click here for more information.
FACS assay shows that Human FGL1, His Tag (Cat. No. FG1-H52Hy) can bind to 293T cells overexpressing human LAG3. The concentration of Human FGL1 is 20 μg/mL.
This web search service is supported by Google Inc.